Innaxon

anti-TLR4 (human), mAb (2E11)

CHF 820.00
In stock
IAX-400-003-C100100 µgCHF 820.00
More Information
Product Details
Synonyms Toll-like Receptor 4; TOLL; hToll; CD284; ARMD10
Product Type Monoclonal Antibody
Properties
Clone 2E11
Isotype Mouse IgG1
Source/Host Purified from concentrated hybridoma tissue culture supernatant.
Immunogen/Antigen Recombinant human TLR4.
Application

FACS: Use at a starting concentration 1-10 μg/ml. 
ICC: Use at a starting concentration 1-10 μg/ml. 
Optimal conditions must be determined individually for each application.

Crossreactivity Human
Specificity

Recognizes the extracellular domain of human TLR4. Does not cross-react with mouse TLR4. Other species not tested.

Purity ≥95% (SDS-PAGE)
Concentration 1mg/ml
Formulation Liquid. In PBS, sucrose, PEG, 0.09% sodium azide.
Isotype Negative Control

Mouse IgG1

Other Product Data

Click here for Original Manufacturer Product Datasheet: Our product description may differ slightly from the original manufacturers product datasheet.

Accession Number

O00206

Declaration Manufactured by Innaxon.
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice After opening, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
Keep sterile.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Description

TLR4 (Toll-like Receptor 4) is a member of the Toll-like receptor (TLR) family which plays a fundamental role in pathogen recognition and activation of innate immunity. It was the first TLR identified TLR in mammals and most studied member of the TLR family. TLR4 recognizes the active lipid A component of lipopolysaccharide (LPS) from Gram-negative bacteria in conjunction with LY96 (also referred to MD-2), CD14 and LPS-binding protein (LBP) and consequently mediates the innate immune response to bacterial lipopolysaccharide (LPS). Additionally, it is also involved in LPS-independent responses triggered by endogenous DMAPs, such as heat shock proteins (HSPs) or HMGB1. TLR4 signals via MYD88, TIRAP and TRAF6, leading to NF-κB activation, cytokine secretion and the inflammatory response in various cell types. In complex with TLR6, it was shown to promote sterile inflammation in monocytes/macrophages in response to oxidized low-density lipoprotein (oxLDL) or amyloid-β 42. TLR4-mediated inflammation, triggered by exogenous or endogenous ligands, is involved in several acute and chronic diseases, having a pivotal role as amplifier of the inflammatory response. The potency with which this TLR activates inflammatory pathways makes it an ideal target for therapeutic intervention and adjuvant development. A broad range of clinical studies have examined the adjuvant activity of TLR4 activators in vaccines against infectious and tumor antigens.

This antibody detects human TLR4 in the absence and presence of MD2 (tested on THP-1 human macrophages). It does not block LPS-mediated activation of human TLR4 (as tested by NFκB activation).

Product References
  1. TLR4 antagonist FP7 inhibits LPS-induced cytokine production and glycolytic reprogramming in dendritic cells, and protects mice from lethal influenza infection: L. Perrin-Cocon, et al.; Sci. Rep. 7, 40791 (2017)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.